In summary, our study have found miR-302a enhance the sensitivity of acute myeloid leukemia cell lines to VP-16 by targeting Rad52 and in part via the AKT/Gsk-3β/β-catenin signaling cascade. The gene discussed is AKT1; the disease is acute myeloid leukemia.